SJ733

Kentucky/Eisai

Product vision
  • Part of a single-exposure radical cure

  • Transmission-blocking activity

MoA
  • PfATP4 inhibitor
Key features
  • Novel chemotype for clinically-validated pathway; First validated new molecular target in 20 years: very rapid killing of parasites

  • Good physical properties and developability

  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for over 8 days is 500mg

Challenges
  • Cost of goods: chiral molecule

  • Potential variability in human PK

Status
  • First-in-human study recruiting

Next milestone
  • Complete first in human studies with three-day multiple, rising dose

Previously
  • Name (+)-SJ000557733; Discovery Partnership with St Jude Children’s Research Hospital and Rutgers University

MMV Project Director
  • Dr Lidiya Bebrevska